Plasminogen Activator Inhibitor 1 for Predicting Sepsis Severity and Mortality Outcomes : A Systematic Review and Meta-Analysis
Research output: Journal Publications and Reviews › RGC 21 - Publication in refereed journal › peer-review
Author(s)
Detail(s)
| Original language | English |
|---|---|
| Article number | 1218 |
| Number of pages | 6 |
| Journal / Publication | Frontiers in Immunology |
| Volume | 9 |
| Online published | 18 Jun 2018 |
| Publication status | Published - Jun 2018 |
| Externally published | Yes |
Link(s)
| DOI | DOI |
|---|---|
| Attachment(s) | Documents
Publisher's Copyright Statement
|
| Link to Scopus | https://www.scopus.com/record/display.uri?eid=2-s2.0-85048624666&origin=recordpage |
| Permanent Link | https://scholars.cityu.edu.hk/en/publications/publication(fd8260b0-7977-4b34-939d-c101d5a268df).html |
Abstract
Objectives: Plasminogen activator inhibitor-1 (PAI-1), a crucial regulator of fibrinolysis, is increased in sepsis, but its values in predicting disease severity or mortality outcomes have been controversial. Therefore, we conducted a systematic review and meta-analysis of its predictive values in sepsis.
Methods: PubMed and Embase were searched until August 18, 2017 for studies that evaluated the relationships between PAI-1 levels and disease severity or mortality in sepsis.
Results: A total of 112 and 251 entries were retrieved from the databases, of which 18 studies were included in the final meta-analysis. A total of 4,467 patients (36% male, mean age: 62 years, mean follow-up duration: 36 days) were analyzed. PAI-1 levels were significantly higher in non-survivors than survivors [odds ratios (OR): 3.93, 95% confidence interval (CI): 2.31-6.67, P <0.0001] and in patients with severe sepsis than in those less severe sepsis (OR: 3.26, 95% CI: 1.37-7.75, P = 0.008).
Conclusion: PAI-1 is a significant predictor of disease severity and all-cause mortality in sepsis. Although the predictive values of PAI-1 reached statistical significance, the clinical utility of PAI-1 in predicting outcomes will require carefully designed prospective trials.
Methods: PubMed and Embase were searched until August 18, 2017 for studies that evaluated the relationships between PAI-1 levels and disease severity or mortality in sepsis.
Results: A total of 112 and 251 entries were retrieved from the databases, of which 18 studies were included in the final meta-analysis. A total of 4,467 patients (36% male, mean age: 62 years, mean follow-up duration: 36 days) were analyzed. PAI-1 levels were significantly higher in non-survivors than survivors [odds ratios (OR): 3.93, 95% confidence interval (CI): 2.31-6.67, P <0.0001] and in patients with severe sepsis than in those less severe sepsis (OR: 3.26, 95% CI: 1.37-7.75, P = 0.008).
Conclusion: PAI-1 is a significant predictor of disease severity and all-cause mortality in sepsis. Although the predictive values of PAI-1 reached statistical significance, the clinical utility of PAI-1 in predicting outcomes will require carefully designed prospective trials.
Research Area(s)
- plasminogen activator inhibitor-1, sepsis, mortality, meta-analysis, systematic review, DISSEMINATED INTRAVASCULAR COAGULATION, ENDOTHELIAL-CELL ACTIVATION, INTENSIVE-CARE-UNIT, PROTEIN-C ACTIVITY, SEPTIC SHOCK, ORGAN DYSFUNCTION, CRITICALLY-ILL, FIBRINOLYSIS, IDENTIFICATION, POLYMORPHISMS
Citation Format(s)
Plasminogen Activator Inhibitor 1 for Predicting Sepsis Severity and Mortality Outcomes: A Systematic Review and Meta-Analysis. / Tipoe, Timothy L.; Wu, William K. K.; Chung, Lilianna et al.
In: Frontiers in Immunology, Vol. 9, 1218, 06.2018.
In: Frontiers in Immunology, Vol. 9, 1218, 06.2018.
Research output: Journal Publications and Reviews › RGC 21 - Publication in refereed journal › peer-review
Download Statistics
No data available
